BELLUS Health

Committed to addressing chronic disorders triggered by hypersensitization

BELLUS is developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The company's lead asset, BLU-5937, is being developed for the treatment of chronic cough (a cough lasting more than eight week) and chronic pruritus (commonly known as chronic itch).

Status
NASDAQ: BLU
Year of Investment
2020
Strategy
Life Sciences
Location
Quebec